



(12) Translation of
European patent specification

(11) NO/EP 2289518 B1

NORWAY

(19) NO
(51) Int Cl.
A61K 31/4965 (2006.01)
A61P 1/04 (2006.01)
C07D 241/20 (2006.01)

Norwegian Industrial Property Office

(21) Translation Published 2017.03.13

(80) Date of The European Patent Office Publication of the Granted Patent 2016.11.02

(86) European Application Nr. 09770108.0

(86) European Filing Date 2009.06.22

(87) The European Application's Publication Date 2011.03.02

(30) Priority 2008.06.23, JP, 2008162640

(84) Designated Contracting States: AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK TR

(73) Proprietor Nippon Shinyaku Co., Ltd., 14, Kisshoin Nishinosho Monguchicho Minami-ku, Kyoto-shiKyoto 601-8550, JP-Japan

(72) Inventor KYOI, Takashi, 4-36, Hirakawanagusa, Jyoyo-shiKyoto 610-0101, JP-Japan

(74) Agent or Attorney Zacco Norway AS, Postboks 2003 Vika, 0125 OSLO, Norge

(54) Title **THERAPEUTIC AGENT FOR INFLAMMATORY BOWEL DISEASE**

(56) References Cited: EP-A1- 2 246 336
WO-A1-02/088084
WO-A1-2006/055481
WO-A1-2006/058080
JP-A- 10 194 992 B1
KUWANO, KEIICHI; HASHINO, ASAMI; ASAKI, TETSUO; HAMAMOTO, TAISUKE; YAMADA, TETSUHIRO; OKUBO, KAORI; KUWABARA, KENJI: "2-4-[5,6-(Diphenylpyrazin-2-yl)(isopropyl)amino]butoxy-N- (methylsulfonyl) acetamide (NS-304), an orally available and long-acting prostacyclin receptor agonist prodrug", BIOORGANIC & MEDICINAL CHEMISTRY, vol. 322, no. 3, 2007, pages 1181-1188, XP002670411,

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

Patentkrav

5 **1.** 2- $\{4-[N-(5,6\text{-difenylpyrazin-2-yl})\text{-N-isopropyl-amino}]butyloksy\}$ eddiksyre
eller 2- $\{4-[N-(5,6\text{-difenylpyrazin-2-yl})\text{-N-isopropylamino}]butyloksy\}$ -N-
(metylsulfonyl)acetamid eller et farmasøytisk akseptabelt salt derav for
anvendelse i behandling av inflammatorisk tarmsykdom.

10 **2.** Forbindelsen for anvendelse ifølge krav 1, hvori den inflammatoriske
tarmsykdommen er ulcerøs kolitt, Crohns sykdom, tarmtuberkulose, iskemisk
kolitt eller tarmsår assosiert med Behcets sykdom.